Tdap maternal immunization and infant follow-up trials: Immunogenicity, transplacental transfer of pertussis antibodies, safety following pertussis immunization during pregnancy and its impact on infant pertussis immune response

Published: 5 October 2020| Version 1 | DOI: 10.17632/ry6m6zj35w.1
Contributors:
Kirsten Perrett,
Scott Halperin,
Terry Nolan,
Cristina Martínez Pancorbo,
Bruce Tapiéro,
Federico Martinón-Torres,
Zbynek Stranak,
Miia Virta,
Otto Vanderkooi,
Pavel Kosina,
Maria Begoña Encinas Pardilla,
Ignacio CRISTOBAL,
Gian Vicenzo Zuccotti,
Lusine Kostanyan,
Nadia Meyer,
Maria Angeles Ceregido,
Brigitte Cheuvart,
Sherine Kuriyakose,
Manuel Marcos Fernández,
miguel angel rodriguez zambrano,
ADRIAN MARTIN,
Juan Eloy Asenjo de la Fuente,
Maria Dolores Camacho Marín,
María de la Calle Fernández-Miranda,
Yolanda Romero Espinar,
Paola Giovanna Marchisio,
paolo manzoni,
Alfonso Carmona Martínez,
José García-Sicilia,
JOSE MANUEL MERINO ARRIBAS,
María José Cilleruelo Ortega,
Mariano Miranda Valdivieso,
Begoña Arias Novas,
Jose Tomas Ramos Amador,
Felix Omeñaca,
manuel baca,
Narcisa Mesaros

Description

This video supports the two published articles by KP Perrett, et al. Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial. Vaccine. 2020;38(8):2095-2104, and KP Perrett, et al. Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial. Vaccine. 2020;38(8):2105-2114. These articles describe the results of two clinical trials, respectively. First study - a maternal immunization trial which assessed the safety and immunogenicity of a reduced antigen content diphtheria-tetanus-acellular pertussis (Tdap) vaccination during pregnancy, as well as the transfer of maternal pertussis antibodies through the umbilical cord. Second study - an infant follow-up study which assessed the safety and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus and Haemophilus influenza type B vaccine (DTPa-HBV-IPV/Hib) when administered to healthy infants born to mothers vaccinated in the maternal immunization trial.

Files

Institutions

GlaxoSmithKline Biologicals SA

Categories

Vaccine, Immunization, Infant, Pregnancy, Infectious Disease Prevention, Pertussis, Human Vaccines for Infectious Disease

License